A phase I study to characterize the pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Phase of Trial: Phase I
Latest Information Update: 13 May 2013
At a glance
- Drugs Topotecan (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 15 Oct 2008 Actual start date changed from Nov 2006 to Sep 2006 as reported by ClinicalTrials.gov.
- 15 Jan 2008 Status changed from in progress to completed.
- 27 Jul 2007 Status change from recruiting to in progress.